Jan 6, 2010
By:
George Koroneos, Online Content & News Editor
It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon.
|
Jan 6, 2010
By:
George Koroneos, Online Content & News Editor
A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen.
|
Dec 9, 2009
By:
George Koroneos, Online Content & News Editor
Drug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle.
|
Dec 2, 2009
By:
George Koroneos, Online Content & News Editor
With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions.
|
Nov 18, 2009
By:
George Koroneos, Online Content & News Editor
Nearly 70 pharma execs, new media mavens, and even Joe Q. Public packed last week's FDA social media hearings to plead for some form of guidance on how to handle Tweets, blog comments, and off label discussions online.
|
Nov 4, 2009
By:
George Koroneos, Online Content & News Editor
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
|
Oct 28, 2009
By:
George Koroneos, Online Content & News Editor
The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program.
|
Oct 21, 2009
By:
George Koroneos, Online Content & News Editor
The third quarter reports are in, and Pfizer's profits are up but sales are down. The company is compensating for looming patent expirations with layoffs and restructuring; is it enough to boost sales?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
